Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Re: Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Zuiverloon TCM, Theodorescu D.

Eur Urol. 2019 Apr;75(4):694. doi: 10.1016/j.eururo.2018.12.019. Epub 2019 Jan 17. No abstract available.

PMID:
30661731
2.

PD-L1 Antibody Comparison in Urothelial Carcinoma.

Rijnders M, van der Veldt AAM, Zuiverloon TCM, Grünberg K, Thunnissen E, de Wit R, van Leenders GJLH.

Eur Urol. 2019 Mar;75(3):538-540. doi: 10.1016/j.eururo.2018.11.002. Epub 2018 Nov 27. No abstract available.

PMID:
30497882
3.

Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines.

Zuiverloon TCM, de Jong FC, Costello JC, Theodorescu D.

Bladder Cancer. 2018 Apr 26;4(2):169-183. doi: 10.3233/BLC-180167.

4.

Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.

Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM.

Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2. Review.

PMID:
29496372
5.

Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.

Zuiverloon TCM, de Jong FC, Theodorescu D.

Oncology (Williston Park). 2017 Dec 15;31(12):855-62. Review.

6.

Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.

Zuiverloon TC, Theodorescu D.

Pharmacogenomics. 2017 Aug;18(12):1167-1178. doi: 10.2217/pgs-2017-0055. Epub 2017 Jul 26. Review.

PMID:
28745580
7.

Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.

Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA.

Urol Oncol. 2016 Oct;34(10):437-51. doi: 10.1016/j.urolonc.2016.05.030. Epub 2016 Sep 15. Review.

PMID:
27641313
8.

Targeted therapies in bladder cancer: an overview of in vivo research.

van Kessel KE, Zuiverloon TC, Alberts AR, Boormans JL, Zwarthoff EC.

Nat Rev Urol. 2015 Dec;12(12):681-94. doi: 10.1038/nrurol.2015.231. Epub 2015 Sep 22. Review.

PMID:
26390971
9.

Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward?

Zuiverloon TC, Zwarthoff EC.

Eur Urol. 2016 Feb;69(2):201-2. doi: 10.1016/j.eururo.2015.07.010. Epub 2015 Jul 21. No abstract available.

PMID:
26209036
10.

Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications.

van Rhijn BW, Musquera M, Liu L, Vis AN, Zuiverloon TC, van Leenders GJ, Kirkels WJ, Zwarthoff EC, Boevé ER, Jöbsis AC, Bapat B, Jewett MA, Zlotta AR, van der Kwast TH.

Mod Pathol. 2015 May;28(5):695-705. doi: 10.1038/modpathol.2014.154. Epub 2014 Nov 28.

11.

Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.

Allory Y, Beukers W, Sagrera A, Flández M, Marqués M, Márquez M, van der Keur KA, Dyrskjot L, Lurkin I, Vermeij M, Carrato A, Lloreta J, Lorente JA, Carrillo-de Santa Pau E, Masius RG, Kogevinas M, Steyerberg EW, van Tilborg AA, Abas C, Orntoft TF, Zuiverloon TC, Malats N, Zwarthoff EC, Real FX.

Eur Urol. 2014 Feb;65(2):360-6. doi: 10.1016/j.eururo.2013.08.052. Epub 2013 Sep 7.

PMID:
24018021
12.

Hypermethylation of the polycomb group target gene PCDH7 in bladder tumors from patients of all ages.

Beukers W, Hercegovac A, Vermeij M, Kandimalla R, Blok AC, van der Aa MM, Zwarthoff EC, Zuiverloon TC.

J Urol. 2013 Jul;190(1):311-6. doi: 10.1016/j.juro.2013.01.078. Epub 2013 Jan 28.

PMID:
23369722
13.

Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.

Zuiverloon TC, Beukers W, van der Keur KA, Nieuweboer AJ, Reinert T, Dyrskjot L, Orntoft TF, Zwarthoff EC.

J Urol. 2013 May;189(5):1945-51. doi: 10.1016/j.juro.2012.11.115. Epub 2012 Nov 28.

PMID:
23201384
14.

FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.

van Kessel KE, Kompier LC, de Bekker-Grob EW, Zuiverloon TC, Vergouwe Y, Zwarthoff EC, Steyerberg EW.

J Urol. 2013 May;189(5):1676-81. doi: 10.1016/j.juro.2012.11.005. Epub 2012 Nov 6.

PMID:
23142690
15.

Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR.

Dyrskjøt L, Reinert T, Novoradovsky A, Zuiverloon TC, Beukers W, Zwarthoff E, Malats N, Real FX, Segersten U, Malmström PU, Knowles M, Hurst C, Sorge J, Borre M, Orntoft TF.

Br J Cancer. 2012 Oct 9;107(8):1392-8. doi: 10.1038/bjc.2012.412. Epub 2012 Sep 13.

16.

Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.

van Rhijn BW, Liu L, Vis AN, Bostrom PJ, Zuiverloon TC, Fleshner NE, van der Aa MN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, Bapat B, van der Kwast TH, Zlotta AR.

BJU Int. 2012 Oct;110(8):1169-76. doi: 10.1111/j.1464-410X.2012.10996.x. Epub 2012 Mar 27.

17.

Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review.

Zuiverloon TC, Nieuweboer AJ, Vékony H, Kirkels WJ, Bangma CH, Zwarthoff EC.

Eur Urol. 2012 Jan;61(1):128-45. doi: 10.1016/j.eururo.2011.09.026. Epub 2011 Oct 6. Review.

PMID:
22000498
18.

A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.

Zuiverloon TC, Beukers W, van der Keur KA, Munoz JR, Bangma CH, Lingsma HF, Eijkemans MJ, Schouten JP, Zwarthoff EC.

BJU Int. 2012 Mar;109(6):941-8. doi: 10.1111/j.1464-410X.2011.10428.x. Epub 2011 Jul 14.

19.

Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay.

Zuiverloon TC, Tjin SS, Busstra M, Bangma CH, Boevé ER, Zwarthoff EC.

J Urol. 2011 Aug;186(2):707-12. doi: 10.1016/j.juro.2011.03.141. Epub 2011 Jun 17.

PMID:
21683397
20.

No evidence of FGFR3 mutations in prostate cancer.

Zuiverloon TC, Boormans JL, Trapman J, van Leenders GJ, Zwarthoff EC.

Prostate. 2011 May;71(6):637-41. doi: 10.1002/pros.21279. Epub 2010 Oct 18.

PMID:
20957671
21.

Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer.

van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, van der Kwast TH.

Eur Urol. 2010 Sep;58(3):433-41. doi: 10.1016/j.eururo.2010.05.043. Epub 2010 Jun 9.

PMID:
20646825
22.

Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.

Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, Zwarthoff EC.

Clin Cancer Res. 2010 Jun 1;16(11):3011-8. doi: 10.1158/1078-0432.CCR-09-3013. Epub 2010 Apr 19.

23.

In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report.

Zuiverloon TC, Abas CS, van der Keur KA, Vermeij M, Tjin SS, van Tilborg AG, Busstra M, Zwarthoff EC.

BMC Urol. 2010 Feb 26;10:5. doi: 10.1186/1471-2490-10-5.

24.

A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene.

Hurst CD, Zuiverloon TC, Hafner C, Zwarthoff EC, Knowles MA.

BMC Res Notes. 2009 Apr 29;2:66. doi: 10.1186/1756-0500-2-66.

25.

A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus.

Seelen MA, van der Bijl EA, Trouw LA, Zuiverloon TC, Munoz JR, Fallaux-van den Houten FC, Schlagwein N, Daha MR, Huizinga TW, Roos A.

Rheumatology (Oxford). 2005 Jan;44(1):111-9. Epub 2004 Oct 12.

PMID:
15479757
26.

Antibody-mediated activation of the classical pathway of complement may compensate for mannose-binding lectin deficiency.

Roos A, Garred P, Wildenberg ME, Lynch NJ, Munoz JR, Zuiverloon TC, Bouwman LH, Schlagwein N, Fallaux van den Houten FC, Faber-Krol MC, Madsen HO, Schwaeble WJ, Matsushita M, Fujita T, Daha MR.

Eur J Immunol. 2004 Sep;34(9):2589-98.

Supplemental Content

Loading ...
Support Center